Ed McGough - Alcon AG Senior Operations
| ALC Stock | USD 88.23 0.99 1.13% |
Executive
Ed McGough is Senior Operations of Alcon AG
| Age | 63 |
| Address | Chemin de Blandonnet 8, Geneva, Switzerland, 1214 |
| Phone | 41 589 112 110 |
| Web | https://www.alcon.com |
Alcon AG Management Efficiency
The company has Return on Asset of 0.0255 % which means that on every $100 spent on assets, it made $0.0255 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0559 %, implying that it generated $0.0559 on every 100 dollars invested. Alcon AG's management efficiency ratios could be used to measure how well Alcon AG manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.04. At present, Alcon AG's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.76, whereas Total Assets are forecasted to decline to about 24.5 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shiela Vinczeller | AptarGroup | 60 | |
| Nicholas Khadder | The Cooper Companies, | 50 | |
| Kathy DePadua | West Pharmaceutical Services | N/A | |
| Laura Piccinini | AngioDynamics | 55 | |
| Juan Serna | AngioDynamics | N/A | |
| Mary Skafidas | AptarGroup | N/A | |
| Marry Skafidas | AptarGroup | N/A | |
| Scott Centea | AngioDynamics | 45 | |
| Michele Polinsky | West Pharmaceutical Services | N/A | |
| Rudy Poussot | West Pharmaceutical Services | N/A | |
| Lawrence Keusch | Teleflex Incorporated | N/A | |
| Jan MD | Haemonetics | N/A | |
| Michelle Fox | Teleflex Incorporated | N/A | |
| Howard Cyr | Teleflex Incorporated | N/A | |
| Kerri DiPietro | Haemonetics | N/A | |
| Christian Voigtlander | ICU Medical | 56 | |
| Daniel Ackerman | AptarGroup | 51 | |
| Clay Fradd | ICU Medical | N/A | |
| Rajeev Varma | Haemonetics | N/A | |
| Laurie Miller | Haemonetics | 50 | |
| John CFA | West Pharmaceutical Services | N/A | |
Management Performance
| Return On Equity | 0.0559 | ||||
| Return On Asset | 0.0255 |
Alcon AG Leadership Team
Elected by the shareholders, the Alcon AG's board of directors comprises two types of representatives: Alcon AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alcon. The board's role is to monitor Alcon AG's management team and ensure that shareholders' interests are well served. Alcon AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alcon AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dieter Spaelti, Independent Director | ||
| Daniel Cravens, Vice Relations | ||
| Arthur MD, Executive Director | ||
| Ian Bell, President - Global Business and Innovation | ||
| Royce Bedward, General VP | ||
| Michael Onuscheck, President - Global Businesses and Innovation | ||
| Ed McGough, Senior Operations | ||
| Terry MD, Chief Safety | ||
| Sergio Duplan, President - North America | ||
| Karen May, Independent Director | ||
| Timothy Stonesifer, Chief Financial Officer | ||
| Michael Ball, Executive Chairman | ||
| Scott Maw, Independent Director | ||
| Ines Poeschel, Independent Director | ||
| Margaret Buckley, Chief Officer | ||
| Leon Fraustro, President - North America | ||
| Thomas Glanzmann, Independent Director | ||
| Arthur Cummings, Independent Director | ||
| S Attias, Head Corporate Development, Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A) | ||
| F Ball, Chairman of the Board ( Designate ) | ||
| D Grossman, Independent Vice Chairman of the Board, Lead Independent Director | ||
| Lynn Bleil, Independent Director | ||
| Dieter Spalti, Independent Director | ||
| Franck Leveiller, Head VP | ||
| David Endicott, Chief Executive Officer, Director | ||
| Kimberly Martin, VP Officer | ||
| Royce JD, General VP | ||
| Rajkumar Narayanan, Senior Vice President - Operational Strategy, Chief Transformation Officer | ||
| Ines Poschel, Independent Director | ||
| SueJean Lin, Senior Vice President, Chief Information and Transformation Officer | ||
| Laurent Attias, Head Corporate Development, Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A) |
Alcon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alcon AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0559 | ||||
| Return On Asset | 0.0255 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 47.24 B | ||||
| Shares Outstanding | 494.6 M | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 66.68 % | ||||
| Number Of Shares Shorted | 3.13 M | ||||
| Price To Earning | 62.60 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alcon AG offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alcon AG's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alcon Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alcon Ag Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alcon AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Alcon Stock refer to our How to Trade Alcon Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alcon AG. If investors know Alcon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alcon AG listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.293 | Earnings Share 2.34 | Revenue Per Share 19.757 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0255 |
The market value of Alcon AG is measured differently than its book value, which is the value of Alcon that is recorded on the company's balance sheet. Investors also form their own opinion of Alcon AG's value that differs from its market value or its book value, called intrinsic value, which is Alcon AG's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alcon AG's market value can be influenced by many factors that don't directly affect Alcon AG's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alcon AG's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alcon AG is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alcon AG's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.